Nephros, Inc. (NEPH) Stock

Understand Nephros, Inc.: how it makes money

Nephros, Inc. sells high-performance water solutions for medical and commercial customers, including ultrafiltration products used in dialysis centers and hospitals to remove contaminants and help prevent infection from waterborne pathogens. It makes money by selling these water-filtration and related systems and products to healthcare and other facilities that need treated water.

The companys profit engine is the installed base at customer facilities, since its ultrafiltration and related pathogen prevention solutions are used in dialysis centers and hospitals, and performance is closely tied to how many Active Customer Sites it supports over time.

Business quality (Mixed): Strengths are clear product application areas (dialysis, hospitals, pathogen prevention) and a directly relevant operating metric set (Active Customer Sites, Customer Retention Rate). The main limitation is that the provided data does not give a clean, usable revenue split across the companys three stated reportable segments.

Valuation: At 52× earnings, NEPH trades 59% above the Medical Equipment average (32×). Note: one-time items can distort reported P/E.

Bull case

• Active Customer Sites and retention: The company reports 1,676.0 Active Customer Sites and a Customer Retention Rate of 90.0%, which suggests ongoing utilization of its water solutions at customer facilities.
• Multiple healthcare use cases for the same core water-solution theme: Its ultrafiltration products are used in dialysis centers to remove biological contaminants from water and in hospitals to prevent infection from waterborne pathogens, supporting demand across different care settings.
• Three operating segments: Management reports three segments, Water Filtration, Pathogen Detection, and Renal Products, which can diversify where solutions are applied in the healthcare and commercial markets.

Bear case

• Thin operating profitability in the latest period: For the period ended 2026-03-31, operating margin is 1.9%, leaving limited room for cost increases or demand softness.
• Segment revenue clarity gap in the provided dataset: Although the business description identifies three segments, the provided segment revenue breakdown does not map cleanly to Water Filtration, Pathogen Detection, and Renal Products, which makes it harder to assess segment drivers of profitability.
• Revenue scale appears very small in the provided numbers: The dataset shows revenue_b as 0.0 for 2026-03-31, and several segment revenue candidates are also listed as 0.0, so conclusions about revenue momentum should be treated cautiously based on the information provided.

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

• Sharps Technology, Inc. (STSS)
• DarioHealth Corp. (DRIO)
• Sensus Healthcare, Inc. (SRTS)
• Spectral AI, Inc. (MDAI)
• Xtant Medical Holdings, Inc. (XTNT)
• PAVmed Inc. (PAVM)
• SANUWAVE Health, Inc. (SNWV)
• Accuray Incorporated (ARAY)